Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Mar;105(13):232-7.
doi: 10.3238/arztebl.2008.0232. Epub 2008 Mar 28.

Novel therapies in advanced renal cell carcinoma: management of adverse events from sorafenib and sunitinib

Philipp Ivanyi  1 , Thomas Winkler, Arnold Ganser, Christoph Reuter, Viktor Grünwald
Affiliations

Novel therapies in advanced renal cell carcinoma: management of adverse events from sorafenib and sunitinib

Philipp Ivanyi et al. Dtsch Arztebl Int. 2008 Mar.

Abstract

Introduction: Sorafenib and Sunitinib are the first tyrosine kinase inhibitors licensed for the treatment of advanced renal cell carcinoma. In contrast to conventional chemotherapy, targeted therapies have distinct and specific side effects.

Methods: Selective review in Medline and the data base of the American Society of Clinical Oncology on the treatment and side effects of tyrosine kinase inhibitors in renal cell carcinoma, drawing on the authors' own experience.

Results and discussion: Tyrosine kinase inhibitors are characterized by a variety of uncommon side effects, such as lassitude, mucosal inflammation and skin changes. The detection and treatment of adverse events are critical for interdisciplinary cancer treatment in order to ensure patients' safety. This article offers an overview of the unwanted effects of drug therapy in the management of renal cell carcinoma.

Keywords: kinase inhibitor; molecular targeted therapy; renal cell cancer; sorafenib; sunitinib.

PubMed Disclaimer

Comment in

  • Addition.
    Meyer PF. Meyer PF. Dtsch Arztebl Int. 2008 Jul;105(27):499-500; author reply 500. doi: 10.3238/arztebl.2008.0500a. Epub 2008 Jul 4. Dtsch Arztebl Int. 2008. PMID: 19626192 Free PMC article. No abstract available.

References

    1. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005;23:2477–2490. - PubMed
    1. Brugarolas J. Renal-cell carcinoma - molecular pathways and therapies. N Engl J Med. 2007;2:185–187. - PubMed
    1. Müller-Tidow C, Krug U, Brunnberg U, Berdel WE, Serve H. Tyrosinkinasen als Ziele neuer onkologischer Therapien. Dtsch Arztebl. 2007;19:1312–1319.
    1. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon-alpha in metastatic renal-cell carcinoma. N Engl J Med. 2007;2:115–124. - PubMed
    1. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;2:125–134. - PubMed